Now showing items 1-3 of 3

    • Development of an LC-MS/MS method for the quantification of goserelin from Pheroid® formulation 

      Takyi-Williams, John; Erasmus, Linné; Hayeshi, Rose; Grobler, Anne; Magwaza, Martin (Elsevier, 2019)
      The oral route is for many reasons the most common route of drug administration, however, due to gastrointestinal (GI) tract enzymatic stability issues, peptide drugs are administered parenterally. Goserelin is an ...
    • The effect of entrapment of a peptide in Pheroid® on pharmacokinetics and testosterone levels 

      Hayeshi, Rose; Erasmus, Linné; Scholtz, Liezl-Marie; Venter, Kobus; Bester, Cor; Fick, Antoinette; Leussa, Nyango-Nkeh Adrienne; Grobler, Anne (Elsevier, 2019)
      Goserelin is a peptide drug that suppresses levels of testosterone and oestradiol [1]. The current formulation is presented in a sustained-release depot with several approved indications such as treatment of endometriosis, ...
    • Evaluation of the oral delivery of a peptide with Pheroid® technology 

      Erasmus, Linné; Scholtz, Liezl-Marie; Venter, Kobus; Bester, Cor; Fick, Antoinette; Mabena, Jacob; Grobler, Anne; Hayeshi, Rose (Elsevier, 2019)
      Goserelin is a type of hormone therapy used in addition to standard adjuvant therapy. Currently, goserelin is only available as a slow releasing subcutaneous implant but this is an invasive and generally not well- tolerated ...